O ver the last decade, many researchers and clinicians have been intrigued by platelet-rich plasma (PRP) as an adjunct to try to improve the healing potential of musculoskeletal injuries. As we have learned more about the possible clinical applications of PRP, and with positive reports in the lay media [8, 13] , patients have become eager to try PRP and are willing to pay out of pocket for this procedure. The price range for PRP in Cleveland, OH, USA is USD 500 to USD 1000. Physicians can market PRP for clinical use due to a high market demand, a safe user profile, and potential financial benefit.
Because of this interest, it is important for the clinician to understand the state of the science when offering PRP treatments to their patients. Obtained from autologous blood, PRP might provide clinical benefit by modulating proinflammatory cytokines and cell migration seen in healing [2, 6, 11] . It appears that PRP stimulates a robust healing response in chronically inflamed tenocytes [3] .
While the basic science is promising, the clinical benefits remain unproven. Clinicians have attempted to harness the potential of PRP to treat a variety of musculoskeletal issues including sprained ligaments, torn tendons, injured muscles, and osteoarthritis. Although many studies have not shown clinical benefit [9, 12] , there are examples of modest gains in limited situations. A large meta-analysis assessing PRP in ligament and tendon injuries found a reduction in pain specifically for lateral epicondylitis and rotator cuff injures [7] .
When evaluating the use of PRP specifically in treating Achilles tendinopathy, the results have been mixed. Researchers attempted to supplement the standard nonsurgical approach of eccentric calf muscle training with PRP to expedite healing time and improve functional outcomes. While some randomized controlled trials demonstrated improvement in pain and function compared to placebo, others have shown no advantage to injecting with normal saline [5, 10] .
The authors of the current study [14] attempted to reconcile these differences noted in the randomized control trials. The meta-analysis of four high-quality randomized control trials yielded 170 patients, and found no difference between normal saline and PRP injections when measuring VISA-A, tendon thickness, and tendon blood flow with laser Doppler flowmetry.
Where Do We Need To Go?
These inconsistent findings illustrate the chasm between the promise of bench research and proof in the setting of clinical application. While there are many studies utilizing PRP to treat Additionally, it is important to consider the location and number of injections. In their study, Boesen and colleagues [5] suggested that multiple injections with PRP may be superior to a single injection due to prolonged exposure of the tendon to growth factors. While this is a reasonable theory, it is also logical that perforation of the tendinopathic tissue with repeated injections alone stimulates a local inflammatory response to initiate healing. Their study compared a single steroid injection, a single saline injection, and four PRP injections. The number of injections alone, regardless of the substance injected, may account for differences and should be considered in future studies.
In the current study, Zhang and colleagues [14] also noted that they performed intratendinous or peritendinous injections under ultrasound guidance. To our knowledge, there is no study demonstrating the superiority of either injection technique. If the diseased portion of the tendon were identifiable on imaging, intratendinous injection targeted to this area would likely be most effective. Unfortunately, the ability of the clinician to reliably target the location of tendinopathy is limited. Peritendinous injection would be more likely to bathe the entire tendon and be reproducible by clinicians.
Zhang and colleagues [14] used eccentric calf training, an effective protocol that Alfredson and colleagues [1] popularized for the treatment of chronic Achilles tendinitis, in conjunction with PRP injections in all included randomized controlled trials. Details about the rehabilitation regimen, in addition to patient compliance, must be carefully planned and reported, as this can be a confounding variable in any future trial.
We should also consider appropriate followup time in treating Achilles tendonitis. Followup time in the current study ranged from as little as 3 months to as long as a 1 year. As chronic tendinitis may take months to years to resolve, longer followup studies would be essential.
How Do We Get There?
A multicenter, blinded, randomized controlled trial with a robust study population and long-term (several years) followup that compares placebo with PRP injections is needed to draw reliable conclusions. While challenging to coordinate on a large scale, given the high patient demand for PRP and its safe profile, patient enrollment should be possible in this context. However, before initiating a multicenter study, smaller investigations are necessary to plan the specifics of an effective protocol.
Cohort studies can assess the dose relationship of platelet concentration and cytological parameters with imaging and patient reported outcomes. These would help establish a minimum threshold for an effective sample. Smaller studies, evaluating the effects of PRP on different patient cohorts, would also be beneficial, as Achilles tendonitis affects both young athletes and older, lower-demand patients. Additional trials focusing on injection number and location with periodic ultrasound or MRI followup may help determine the optimal injection protocol.
While the current study does not find sufficient evidence to support PRP for chronic Achilles tendinitis, futures trials with refined methodology may unlock the potential of PRP. It is important for our profession to rely on good science when making treatment decisions to avoid the ethical pitfalls of promising and highly publicized, but unproven therapies.
